Trigeminal Neuralgia Treatments Compared: 10-Year Pain-Free Rates

Quick Answer: Carbamazepine or oxcarbazepine comes first: in a real-world series of 354 patients, 88.3% responded to carbamazepine and 90.9% to oxcarbazepine, though side effects forced 29.6% and 12.6% to stop or cut the dose too far. When drugs fail, the procedures split into two groups. The percutaneous ones (radiofrequency, glycerol, balloon compression) relieve pain quickly in most patients but wear off: 57.7% of radiofrequency patients were still pain-free at 5 years in the largest series, and only 19% of glycerol patients were. Microvascular decompression is open surgery, but 70% of patients were pain-free without medication 10 years later. Gamma Knife radiosurgery is the least invasive: 30% were controlled at 10 years. No randomised trial has compared decompression with any of the others, and the gentler “pulsed” form of radiofrequency helped 2 of 20 patients in the only trial that tested it.

This page puts the published results for each treatment in one place, with the source and the size of each study. The figures come from different groups of patients, measured in different ways, so they show the shape of each option rather than a strict ranking. The choice between them is made with a neurologist and a neurosurgeon, and depends on MRI findings, age and general health.

Trigeminal neuralgia treatments compared: the results side by side

Medicines first: carbamazepine and oxcarbazepine

The European Academy of Neurology’s 2019 guideline is plain about the order: “For long-term treatment, carbamazepine or oxcarbazepine are recommended as drugs of first choice.” The earlier joint guideline from the American Academy of Neurology and the European Federation of Neurological Societies put the difference in a single phrase: carbamazepine has the “stronger evidence” and oxcarbazepine the “better tolerability.”

Carbamazepine has been the standard for decades, but the trials behind it are thin. A 2014 Cochrane review of carbamazepine for nerve pain found that “no trial was longer than four weeks”, and none met its higher evidence standards. Across four of those studies, 65% of people on carbamazepine had at least one side effect, against 27% on placebo.

The clearest long-term picture comes from clinic records. In a 2021 study from Sapienza University in Rome, 354 patients with trigeminal neuralgia were followed on carbamazepine or oxcarbazepine. The first response rates were high, 88.3% and 90.9%. But side effects occurred in 43.6% of carbamazepine patients and 30.3% of oxcarbazepine patients, and “major side effects caused treatment interruption or dosage reduction to an unsatisfactory level” in 29.6% and 12.6%. Patients whose neuralgia had another cause, or no visible cause on MRI, did worse than those with a blood vessel pressing on the nerve.

Carbamazepine’s US label carries a boxed warning. Serious skin reactions, toxic epidermal necrolysis and Stevens-Johnson syndrome, are estimated at “1 to 6 per 10,000 new users” in mainly white populations, and “about 10 times higher” in some Asian countries, where the risk is linked to a gene variant, HLA-B*1502. The label also warns about aplastic anaemia and agranulocytosis. These are the reasons blood tests and, for some patients, genetic testing come before the first prescription.

When the drugs fail or cannot be tolerated, the guideline recommends that “patients should be offered surgery.”

Radiofrequency thermocoagulation: fast relief, often repeated

In percutaneous radiofrequency thermocoagulation, a needle is passed through the cheek to the Gasserian ganglion at the base of the skull, under X-ray guidance. The tip is heated to make a controlled lesion in the nerve fibres carrying the pain. In the Ankara series, patients were kept light enough to cooperate, because their responses let the surgeon make “selective, controlled lesions”.

The largest published series is from Ankara University: 1,600 patients treated between 1974 and 1999, with 2,138 procedures. Acute pain relief was achieved in 97.6%. After a single procedure, 57.7% were pain-free at 5 years, 52.3% at 10 years and 41% at 20 years. Because the procedure can be repeated, the proportion with pain relief after one or more procedures was much higher: 94.2% at 10 years. In all, 76% of patients needed only one procedure.

The cost is in sensation. The same series reported a diminished corneal reflex in 5.7%, weakness of the chewing muscles in 4.1%, keratitis in 0.6% and anaesthesia dolorosa, a painful numbness that can be harder to treat than the neuralgia, in 0.8%. There were no deaths.

A 2008 review of every surgical series with at least 5 years of follow-up, co-written by the same Ankara surgeon, gives the other side of fast relief: the average pain-free rate after radiofrequency was 50.4% at 5 years, and the recurrence rate was 46%, the highest of the options compared.

Pulsed radiofrequency: the gentler version that failed its trial

Pulsed radiofrequency delivers the current in short bursts at a lower temperature, so it does not create a heat lesion. It is offered for several kinds of nerve pain on the promise of relief without numbness. For trigeminal neuralgia, it has been tested in one randomised, double-blind trial, run at Istanbul University and published in 2007.

Forty patients were assigned to conventional or pulsed radiofrequency, 20 in each group. Pain fell significantly in the conventional group. In the pulsed group, pain fell in only 2 of 20 patients, and it came back at 3 months. At that point, “all patients in this group still had intractable pain”, and they were given conventional radiofrequency, after which their pain fell as much as the first group’s. The authors concluded that “unlike CRF, PRF is not an effective method of pain treatment for idiopathic trigeminal neuralgia.” A 2011 Cochrane review of neurosurgical treatments includes the same trial and reports the same result.

Glycerol rhizotomy: good at first, short-lived

In glycerol rhizotomy, the needle reaches the same space behind the ganglion, and glycerol is injected to damage the pain fibres chemically. The most recent large cohort, 86 patients and 132 procedures at the University of Pittsburgh between 2015 and 2024, was published in 2026.

Effective relief at the first visit was 76.9%. It did not last: the proportion with effective relief was 80% at 6 months, 67% at 1 year, 46% at 2 years, 19% at 5 years and 7% at 10 years. Permanent numbness was recorded after 28.3% of procedures, and anaesthesia dolorosa after 2.3%. The title of the paper is its finding: glycerol is “effective in achieving immediate but not long-term pain reduction.”

Balloon compression: fewer eye problems

Balloon compression uses the same route. A small balloon is inflated to compress the ganglion, and the Sydney surgeons note it “can be performed during a brief period of general anesthesia.” The largest series, 496 patients treated in Sydney between 1980 and 1999 and followed for an average of 10.7 years, reported prompt relief after all but one of the successful procedures.

Pain came back within 5 years in 19.2%, and in 31.9% over the whole study. Troublesome dysaesthesia, an abnormal and unpleasant sensation, affected 3.8%, but “corneal anesthesia and anesthesia dolorosa did not” occur. That matters most for pain in the first branch of the nerve, around the eye, where loss of corneal sensation is a risk to the eye itself.

The 2008 long-term review found balloon compression and microvascular decompression gave similar results, and both were better than the other options it compared.

Microvascular decompression: open surgery, the longest relief

Microvascular decompression is the only procedure that does not damage the nerve. Through a small opening behind the ear, the surgeon finds the blood vessel pressing on the trigeminal nerve at the brain stem and separates it, usually with a small pad. It needs a general anaesthetic and a hospital stay.

The landmark report is from Pittsburgh and was published in the New England Journal of Medicine in 1996: 1,185 patients over 20 years, followed with yearly questionnaires for a median of 6.2 years. Ten years after surgery, 70% were free of pain without medication, and another 4% had occasional pain that needed no long-term medicine. Most recurrences happened in the first 2 years; after 10 years, the yearly recurrence rate was below 1%.

The risks are those of brain surgery. There were 2 deaths shortly after the operation (0.2%), 1 brain-stem infarction (0.1%), and hearing loss on the same side in 16 patients (1%). The authors also found that patients who had earlier had a radiofrequency lesion of the ganglion reported more burning and aching facial pain after decompression.

The 2019 European guideline recommends decompression “as first-line surgery in patients with classical TN”, meaning when MRI shows a blood vessel in contact with the nerve. The 2020 review in The Lancet Neurology by the same group calls it “the first-line surgery in medically refractory patients.”

Gamma Knife radiosurgery: no incision, fading control

Stereotactic radiosurgery aims a single high dose of focused radiation at the trigeminal nerve root. There is no incision and no needle, which is why it is often offered to older patients and to those who cannot have a general anaesthetic.

The largest long-term series, 503 patients at the University of Pittsburgh with a median age of 72, was published in 2010. Initial relief that was adequate or better came in 89%. Counting patients whose pain was controlled with or without medication, the figures were 80% at 1 year, 71% at 3 years, 46% at 5 years and 30% at 10 years. New or worse facial numbness developed in 53 patients (10.5%). Patients who developed numbness had better long-term pain control, which is the trade-off at the centre of every destructive procedure.

What no trial has answered

The 2011 Cochrane review of neurosurgical treatments searched for randomised trials of every procedure. It found 11 studies, none that could be pooled, and none on microvascular decompression. Its conclusion: “There is very low quality evidence for the efficacy of most neurosurgical procedures for trigeminal neuralgia,” and “There is little evidence to help comparative decision making about the best surgical procedure.” The 2019 European guideline reached the same point from another direction: “No recommendation can be given for choice between any neuroablative treatments or between them and microvascular decompression in patients with idiopathic TN.”

That is why the table at the top of this page is a set of separate series, not a contest. The radiosurgery series had a median age of 72 and 43% had already had failed surgery, and the studies define “pain-free” in different ways. What the series agree on is the pattern: relief that comes without opening the skull tends to return sooner; the more sensation a destructive procedure removes, the longer the relief tends to last.

How the choice is usually made

• Drugs first. Carbamazepine or oxcarbazepine, with surgery offered when pain is not controlled or the side effects are not tolerable.
• MRI shows a vessel pressing on the nerve. The European guideline recommends microvascular decompression as the first operation, if the patient is fit for surgery.
• No vessel on MRI. The guideline says destructive (neuroablative) treatments “should be the preferred choice.”
• Older or frail patients, or those on blood thinners. Percutaneous procedures or radiosurgery are often considered because they avoid open surgery.
• Pain around the eye. The risk of losing corneal sensation is weighed for each percutaneous method.

We do not link to any product on this page. None of the treatments above can be bought, and the decision belongs with the specialists who can examine you and read your MRI.

Frequently Asked Questions

What is the first treatment for trigeminal neuralgia?

Carbamazepine or oxcarbazepine. The 2019 European Academy of Neurology guideline recommends them as drugs of first choice. In a 354-patient series, 88.3% responded to carbamazepine and 90.9% to oxcarbazepine, though side effects limited treatment in a substantial minority.

Which surgery for trigeminal neuralgia lasts the longest?

Microvascular decompression has the longest results on record: in a series of 1,185 patients, 70% were pain-free without medication 10 years after surgery. It is open brain surgery, with a 0.2% death rate and 1% hearing loss in that series.

How long does radiofrequency treatment for trigeminal neuralgia last?

In the largest series, 1,600 patients in Ankara, 57.7% were pain-free 5 years after a single procedure and 52.3% at 10 years. The procedure can be repeated, and 76% of patients needed only one.

Does pulsed radiofrequency work for trigeminal neuralgia?

Not in the only trial that tested it. In a 2007 randomised trial of 40 patients, pain fell in just 2 of the 20 who had pulsed radiofrequency, and it returned by 3 months. Conventional radiofrequency worked in both groups.

Is Gamma Knife better than microvascular decompression?

No trial has compared them. Gamma Knife avoids surgery, and in a 503-patient series pain was controlled in 46% at 5 years and 30% at 10 years. Decompression lasts longer in published series but carries the risks of an operation.

What is anaesthesia dolorosa?

A painful numbness in the area where sensation has been lost, which can follow destructive procedures on the trigeminal nerve. It was reported after 0.8% of radiofrequency procedures in the Ankara series and 2.3% of glycerol procedures in the Pittsburgh cohort, and in none of the 496 balloon compression patients in Sydney.

Sources

1. Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019;26(6):831-849. PubMed 30860637. Carbamazepine or oxcarbazepine first choice; surgery if pain not controlled or drugs poorly tolerated; microvascular decompression first-line surgery in classical TN; no recommendation between neuroablative treatments or between them and decompression in idiopathic TN; neuroablative preferred if MRI shows no neurovascular contact. Checked 29 October 2026.
2. Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013-28. PubMed 18721143. Carbamazepine “stronger evidence”, oxcarbazepine “better tolerability”; decompression may be considered for the longest pain freedom. Checked 29 October 2026.
3. Bendtsen L, Zakrzewska JM, Heinskou TB, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 2020;19(9):784-796. PubMed 32822636. Checked 29 October 2026.
4. Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014;(4):CD005451. PubMed 24719027. 10 studies, 480 participants; no trial longer than four weeks; adverse events 65% (113/173) vs 27% (47/173) on placebo. Checked 29 October 2026.
5. Di Stefano G, De Stefano G, Leone C, et al. Real-world effectiveness and tolerability of carbamazepine and oxcarbazepine in 354 patients with trigeminal neuralgia. Eur J Pain. 2021;25(5):1064-1071. PubMed 33428801. Responders 88.3% and 90.9%; interruption or inadequate dose 29.6% (53 patients) and 12.6% (22 patients); side effects 43.6% vs 30.3%. Checked 29 October 2026.
6. Tegretol (carbamazepine) prescribing information, boxed warning. DailyMed setid 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053. dailymed.nlm.nih.gov. SJS/TEN 1 to 6 per 10,000 new users, about 10 times higher in some Asian countries; HLA-B*1502; aplastic anemia and agranulocytosis. Checked 29 October 2026.
7. Kanpolat Y, Savas A, Bekar A, Berk C. Percutaneous controlled radiofrequency trigeminal rhizotomy for the treatment of idiopathic trigeminal neuralgia: 25-year experience with 1,600 patients. Neurosurgery. 2001;48(3):524-32. PubMed 11270542. 2,138 procedures, 1974-1999; 76% one procedure; acute relief 97.6%; single procedure 57.7% at 5 years, 52.3% at 10, 41% at 20; 94.2% at 10 years with multiple procedures; corneal reflex 5.7%, masseter 4.1%, keratitis 0.6%, anaesthesia dolorosa 0.8%; no deaths. Checked 29 October 2026.
8. Tatli M, Satici O, Kanpolat Y, Sindou M. Various surgical modalities for trigeminal neuralgia: literature study of respective long-term outcomes. Acta Neurochir (Wien). 2008;150(3):243-55. PubMed 18193149. 28 studies with at least 5 years of follow-up; radiofrequency pain-free 50.4% at 5 years, recurrence 46%; decompression recurrence 18.3%; decompression and balloon compression similar and superior. Checked 29 October 2026.
9. Erdine S, Ozyalcin NS, Cimen A, et al. Comparison of pulsed radiofrequency with conventional radiofrequency in the treatment of idiopathic trigeminal neuralgia. Eur J Pain. 2007;11(3):309-13. PubMed 16762570. 40 patients, 20 per group; pain fell in 2 of 20 with pulsed RF, recurrence at 3 months. Checked 29 October 2026.
10. Bhatia S, Sharma N, Gopakumar A, et al. Percutaneous glycerol rhizotomies are effective in achieving immediate but not long-term pain reduction in patients with trigeminal neuralgia: a contemporary cohort analysis. Clin Neurol Neurosurg. 2026;260:109240. PubMed 41273985. 86 patients, 132 procedures, 2015-2024; immediate 76.9%; 80% at 6 months, 67% at 1 year, 46% at 2, 19% at 5, 7% at 10; permanent hypoesthesia 28.3%; anaesthesia dolorosa 2.3%. Checked 29 October 2026.
11. Skirving DJ, Dan NG. A 20-year review of percutaneous balloon compression of the trigeminal ganglion. J Neurosurg. 2001;94(6):913-7. PubMed 11409519. 496 patients, 531 procedures, 1980-1999, mean follow-up 10.7 years; recurrence 19.2% within 5 years, 31.9% overall; dysaesthesia 3.8%; no corneal anaesthesia or anaesthesia dolorosa. Checked 29 October 2026.
12. Barker FG 2nd, Jannetta PJ, Bissonette DJ, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996;334(17):1077-83. PubMed 8598865. 1,185 patients, median follow-up 6.2 years; 70% excellent at 10 years plus 4% occasional pain; annual recurrence below 1% after 10 years; 2 deaths (0.2%), 1 brain-stem infarction (0.1%), hearing loss 16 patients (1%). Checked 29 October 2026.
13. Kondziolka D, Zorro O, Lobato-Polo J, et al. Gamma Knife stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg. 2010;112(4):758-65. PubMed 19747055. 503 patients, median age 72; initial relief 89%; BNI I-IIIb 80% at 1 year, 71% at 3, 46% at 5, 30% at 10; prior failed surgery 205 (43%); numbness 53 patients (10.5%); 78% at 5 years in those with sensory loss. Checked 29 October 2026.
14. Zakrzewska JM, Akram H. Neurosurgical interventions for the treatment of classical trigeminal neuralgia. Cochrane Database Syst Rev. 2011;(9):CD007312. PubMed 21901707. 11 studies, 496 participants; no microvascular decompression trials met criteria; very low quality evidence. Checked 29 October 2026.